Proactive Investors - Run By Investors For Investors

Chemistree Technology unveils plans for debenture offering

The debentures will mature three years from the date of issue and the debenture units will also consist of 2,000 company share purchase warrants
Businessman looking at financial charts
The company is set for a debenture unit offering

Chemistree Technology Inc (CSE:CHM) (OTCMKTS: CHMJF)  is set for an offering of convertible debenture units and has appointed broker Canaccord as the sole bookrunner.

In a short form prospectus, the firm said each debenture unit will consist of one 10% unsecured convertible debenture of the company worth $1,000 with interest payable semi-annually in arrears on June 30 and December 31 of each year, beginning June 30 this year.

WATCH: Chemistree Technology preparing to build greenhouse and production facility in Cali

The debentures will mature three years from the date of issue and the debenture units will also consist of 2,000 company share purchase warrants expiring 36 months after the date of issue.

Each debenture is convertible at $0.50 per share subject to certain adjustments, while each warrant allows the holder one share at an exercise price of $0.70 per share until the expiry date.

The debentures and the warrants comprising the debenture units will separate immediately upon the closing of the offering.

There is no minimum amount of funds that must be raised under the offering, the company noted.

Contact Giles at [email protected]

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full CHM profile View Profile

Chemistree Technology Inc. Timeline

Related Articles

cannabis
August 28 2018
Tidal Royalty provides capital to help grow licenced US cannabis firms in exchange for receiving a percentage of future top-line revenues.
A cannabis plant shown next to an oil-based product
18:30
THC is executing medicinal cannabis strategy in Australia, New Zealand and Canada and is looking to Asian markets.
Sydney Harbour Bridge
January 22 2019
A phase I study in Australia is evaluating a cannabis spray therapeutic in cancer patients.
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use